Taking into account that TS, DHFR, and CK2 are molecular targets in cancer chemotherapies, we have recently undertaken studies on the simultaneous treatment of cancer cells with inhibitors of TS and CK2α [17,18] or DHFR and CK2α [15] searching for a synergistic effect. This evidence concerns the gene TYMS and cancer.